Efficacy and safety of PD-1 blockade-activated neoantigen specific cellular therapy for advanced relapsed non-small cell lung cancer
Abstract Background Due to its strong immunogenicity and tumor specificity, neoplastic antigen has emerged as an immunotherapy target with wide therapeutic prospect and clinical application value. Anti-programmed death-1 (PD-1) antibodies reinvigorate T cell-mediated antitumor immunity. So, we condu...
Saved in:
| Main Authors: | Yun Qiao, Kaiyuan Hui, Chenxi Hu, Mei Wang, Wen Sun, Liang Liu, Changhong Dong, Xiaodong Jiang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-01-01
|
| Series: | Cancer Immunology, Immunotherapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00262-024-03906-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neoantigen load as a predictor of relapse in early-stage NSCLC: features that agonise and antagonise prognosis
by: Linda Ye, et al.
Published: (2025-08-01) -
Identification of shared neoantigens derived from frameshift mutations in the APC gene
by: Peng Zhao, et al.
Published: (2025-05-01) -
Neoantigens: new hope for cancer therapy
by: Yitong Hu, et al.
Published: (2025-03-01) -
Neoantigen immunotherapy: a novel treatment for bladder cancer
by: Ruiyang Lv, et al.
Published: (2025-01-01) -
Shared neoantigens for cancer immunotherapy
by: Anastasia Goloudina, et al.
Published: (2025-06-01)